MDxHealth

MDXH

Capitalización de mercado USD 19.7 M

IRVINE, CA – October 15, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced preliminary unaudited revenue from continuing operations for the third quarter ended September 30, 2026, and suspends its full-year 2026 revenue guidance of $110–115 million. The Company expects to report third quarter 2026 revenue from continuing operations of approximately $22.7 million, compared to $22.7 million in the third quarter of 2025 (re-presented to exclude Resolve mdx, which is reported as a discontinued operation).

MDxHealth SA (NASDAQ:MDXH) stock skyrocketed on Friday after the diagnostic company reported mixed quarterly earnings.

MDxHealth SA (MDXH) Q2 2026 Earnings Call Transcript

MDxHealth SA (MDXH) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.15 per share a year ago.

Second quarter r evenue gr owth of 1 6 % to $ 2 7 . 2 million Conference call with Q&A today at 4 : 3 0 PM EST / 22 : 30 CET

Company to Host Conference Call with Live Q&A, August 13, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – July 30, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the second quarter ended June 30, 2026, after market close on Thursday, August 13, 2026. Title: Mdxhealth Presents Second Quarter 2026 Financial Results andCorporate Update Conference Call and Webcast Date: August 13, 2026 Time: 4:30pm ET/ 22:30 CET Conference Call D ial-in Details: United States: 1-833-309-3473 Belgium: 0800 72 519 United Kingdom: 0808 101 1183 Conference ID:         MDX2Q26 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1768432&tp_key=e5dee9dbef The webcast should be accessed 15 minutes prior to the conference call start time.

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency IRVINE, California – July 24, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leader in urology-focused precision diagnostics, today announced that the Company received an additional notification letter (the “Additional Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) related to the recent reduction in the price for the Company's ordinary shares. The initial notice, reported by the Company in its Form 6-K filed on July 2, 2026, related to the Company's non-compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing.

IRVINE, California – July 2, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated June 30, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification.

Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial IRVINE, California – June 29, 2026– Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced the peer-reviewed publication of the Oxford GPS-ProMPT study in European Urology Oncology, one of the world's leading journals in genitourinary oncology. The publication represents the first major peer-reviewed milestone from the Oxford collaboration and serves as the foundation for evidence to be produced by the landmark GPS-ProtecT study.

MDxHealth NASDAQ: MDXH reported first-quarter 2026 revenue of $27.4 million while announcing a strategic exit from its Resolve UTI testing business and the planned closure of its Plano, Texas, laboratory facility, a move executives said will sharpen the company's focus on prostate cancer diagnostics.